Adrangi mounts short attack on 'worthless' drugs of Sanofi ally by Nick Paul Taylor Tuesday, January 28, 2020 The short seller thinks Principia’s approach to the treatment of autoimmune diseases is “misguided” and likely to lead to clinical failures.
Esperion tees up to launch cholesterol-busting meds—affordably by Amirah Al Idrus Tuesday, January 14, 2020 Esperion plans to sell its non-statin cholesterol-fighting drugs at a price that ensures patients prescribed them can actually afford them.
In-demand Schrödinger teams up with Bayer by Ben Adams Thursday, January 9, 2020 New York-based Schrödinger and German pharma Bayer have penned a five-year drug trial tech deal aimed at boosting Bayer's drug discovery efforts.
2. Cablivi by Eric Sagonowsky Cablivi scored an FDA nod in February in combination with plasma exchange and immunosuppression for the treatment of acquired thrombotic thrombocytopenic purpura.
Alnylam preps next filing as kidney med aces phase 3 by Amirah Al Idrus Tuesday, December 17, 2019 Alnylam's lumasiran beat placebo at helping patients clear oxalate from their kidneys, teeing it up for a 2020 filing.
Sanofi to reshape Onduo-Verily partnership with diabetes exit by Conor Hale Tuesday, December 10, 2019 Sanofi will look to pull back from its three-year-old relationship with Verily and their virtual diabetes clinic, Onduo.
Sanofi eyes FDA filing as orphan blood drug hits late-phase goal by Nick Paul Taylor Tuesday, December 10, 2019 More than half of the participants met the primary endpoint, teeing Sanofi up to file for FDA approval of the complement C1s inhibitor.
Sanofi inks $2.5B Synthorx takeover to gain IL-2 cancer drug by Nick Paul Taylor Monday, December 9, 2019 The takeover, the first of Paul Hudson’s time as CEO, will give Sanofi an IL-2 drug it thinks can become a foundation of future cancer combinations.
Sanofi strategy chief Mansuri set to step away—Chutes & Ladders by Kyle Blankenship Friday, December 6, 2019 Mansuri will step down from Sanofi strategy role; Ratliff takes lead at AMRI after brief LabCorp stint; Caraway taps Williams for chief role.
FDA nixes Lexicon's diabetes hopeful Zynquista—again by Amirah Al Idrus Tuesday, December 3, 2019 The FDA rebuffed Lexicon’s appeal of its rejection of the Type 1 diabetes drug Zynquista. The company plans to plead its case to the agency's CDER.
